The effect of addition of liraglutide to high-dose intensive insulin therapy: A randomized prospective trial

Diabetes, Obesity and Metabolism

Volumn 16, Issue 9, 2014, Pages 827-832

  Lane, W ^a   Weinrib, S ^a   Rappaport, J ^a   Hale, C ^a  

^a Mountain Diabetes and Endocrine Center   (United States)

Author keywords

GLP 1 analogue; Insulin intensive management; Insulin resistance; Insulin therapy; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; INSULIN INFUSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; BODY WEIGHT; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; METABOLISM; OBESITY; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905729436     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12286     Document Type: Article

References (17)

1. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized controlled trial. Ann Intern Med 2011; 154: 103-112.
2. Vora J, Bain SC, Dzida T et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2013; 39: 6-15.
3. Harris M. Medical care for patients with diabetes - epidemiologic aspects. Ann Intern Med 1996; 124: 117-122.
4. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-269.
5. Tzefos M, Olin J. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2012; 44: 1294-1299.
6. Lane WS, Cochran EK, Jackson JA et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009; 15: 71-79.
7. Wulffele MG, Kooy A, Lehert P et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
8. Charbonnel B, Schweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract 2013; 41: 93-107.
9. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
10. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012; 6: 41-46.
11. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011; 13: 592-595.
12. De Vries JH, Bain SC, Rodbard HW et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets. Diabetes Care 2012; 35: 1446-1454.
13. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11(Suppl 3): 26-34.
14. Wilding JPH, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. A randomized trial. Ann Intern Med 2012; 156: 405-415.
15. Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009; 25: 199-207.
16. Alonso N, Julian MT, Puig-Domingo M, Vives-Pi M. Incretin hormones as immunomodulators of atherosclerosis. 2012. Available from URL: http://www.frontiersin.org/Systems_and_Translational_Endocrin-ology. Accessed 1 November 2013.
17. Lonborg J, Kelbaek H, Vejlstrup N et al. Exenatide reduces final infarct size in patients with ST-segment elevation myocardial infarction and short duration of ischemia. Circ Cardiovasc Interv 2012; 5: 288-295.